All In Biotech

NDA 021121 · Janssen Pharms

Concerta

Methylphenidate Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Apr 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Aug 1, 2000

Approved uses

4

Original approval plus efficacy supplements

Registered trials

456

101 Phase 3, 37 recruiting

FAERS reports

24,565

15,132 serious, 790 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION CONCERTA has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including CONCERTA, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with a higher dosage or unapproved methods of administration, such as snorting or injection. Before prescribing CONCERTA, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of CONCERTA, and proper disposal of any unused drug. Throughout CONCERTA treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) and Drug Abuse and Dependence (9.1 , 9.2) ]. WARNING: ABUSE, MISUSE, AND...

What it is approved for

From the label in effect Apr 20, 2026.

CONCERTA is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. Limitations of Use The use of CONCERTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7) and Use in Specific Populations (8.4) ]. CONCERTA is a CNS stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. ( 1 ) Limitations of Use The use of CONCERTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).

Mechanism: Methylphenidate is a central nervous system (CNS) stimulant. The mode of therapeutic action of methylphenidate in the treatment of ADHD is not known. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • CONCERTA · METHYLPHENIDATE HYDROCHLORIDE 27MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CONCERTA · METHYLPHENIDATE HYDROCHLORIDE 36MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CONCERTA · METHYLPHENIDATE HYDROCHLORIDE 54MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CONCERTA · METHYLPHENIDATE HYDROCHLORIDE 18MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylphenidate" as an intervention, any sponsor and status, largest first.

All 456 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,748
  • headache1,273
  • off label use1,230
  • nausea1,120
  • fatigue1,103
  • anxiety1,100
  • insomnia907
  • depression825
  • suicidal ideation825
  • decreased appetite755
  • aggression720
  • disturbance in attention720

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004501
2005509
2006503
2007554
2008549
2009622
2010619
2011561
2012669
2013626
2014639
20152,084
20161,658
20171,486
20181,417
20191,422
20201,208
20211,069
20221,607
20231,970
20241,631
20251,550
20261,111

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 3, 2026

    Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01).

  • Current · updated Nov 3, 2026

    Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01).

  • Current · updated Nov 3, 2026

    Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01).

  • Current · updated Nov 3, 2026

    Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Concerta (Methylphenidate HCl)

2024 spending

$10.5M

Beneficiaries

3,972

19,317 claims

Per beneficiary

$2,654

$13.53 per unit

View as table
YearSpending
2020$4,979,002
2021$5,342,625
2022$6,601,902
2023$14,681,764
2024$10,541,064

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,061 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.